Skip to main content
NFL Biosciences logo

NFL Biosciences — Investor Relations & Filings

Ticker · ALNFL ISIN · FR0014003XT0 LEI · 9695006VJWNTN4UNHA27 PA Professional, scientific and technical activities
Open in API
Filings indexed 184 across all filing types
Latest filing 2023-02-02 Regulatory Filings
Country FR France
Listing PA ALNFL

About NFL Biosciences

https://www.nflbiosciences.com/

NFL Biosciences is a biopharmaceutical company that develops botanical drug candidates for the treatment of addictions. The company's lead product, NFL-101, is a nicotine-free drug candidate for smoking cessation derived from a protein extract of tobacco leaves. Its development pipeline also includes NFL-301, a candidate aimed at reducing excessive alcohol consumption. NFL Biosciences focuses on advancing its products through clinical trials with the goal of licensing them to pharmaceutical companies for commercialization.

Recent filings

Filing Released Lang Actions
NFL Biosciences collaborates with the CEA
Regulatory Filings Classification · 94% confidence The document announces a collaboration between NFL Biosciences and the CEA to study the mechanism of action of their drug candidate NFL-101 using molecular imaging (PET scans). It details the scientific rationale, the teams involved, and the expected outcomes related to clinical studies (CEST0 II and PRECESTO). This type of announcement, focusing on research progress, scientific partnerships, and future licensing attractiveness, does not fit neatly into standard financial reporting categories like 10-K, ER, or IR. It is a specific operational/scientific update. Since it is not a formal regulatory filing (like a 10-K or 8-K equivalent mentioned by name), nor a management change (MANG), nor a financing event (CAP), nor a dividend announcement (DIV), the most appropriate classification is the general regulatory/operational announcement fallback category, RNS, as it is a material announcement to the market about company operations and research.
2023-02-02 English
NFL BIOSCIENCES : Très fort succès de l’augmentation de capital de NFL Biosciences avec plus de 3 millions d’euros levés
Share Issue/Capital Change Classification · 99% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces the "Très fort succès de l'augmentation de capital de NFL Biosciences avec plus de 3 millions d'euros levés" (Very strong success of NFL Biosciences' capital increase with over 3 million euros raised). It details the amounts raised, the subscription price, the allocation of funds, and the resulting shareholder structure changes due to the issuance of new shares. This content directly relates to fundraising, financing activities, and capital structure changes. This aligns perfectly with the definition for Capital/Financing Update (CAP). Although it is a detailed announcement, it is not the full annual report (10-K) or a comprehensive interim report (IR), but rather a specific corporate action announcement.
2023-01-31 French
NFL BIOSCIENCES: Very successful capital increase for NFL Biosciences with over €3 million raised
Share Issue/Capital Change Classification · 99% confidence The document is explicitly titled a "PRESS RELEASE" and announces the "Very successful capital increase for NFL Biosciences with over €3 million raised." It details the subscription amounts, pricing, allocation of funds, and changes to the shareholding structure resulting from the issuance of new shares. This content directly relates to fundraising, financing activities, and capital structure changes. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not an earnings release (ER), an annual report (10-K), or a simple announcement of a report (RPA/RNS), as it contains the substantive details of the financing event itself.
2023-01-31 English
NFL Biosciences launches a round of fundraising for approximately 2.5 million euros
Capital/Financing Update Classification · 98% confidence The document is explicitly titled 'PRESS RELEASE' and announces the 'launch of a round of fundraising for approximately 2.5 million euros' involving capital increases, share issuance, and pricing details for professional and retail investors. This content directly relates to the company raising capital through issuing new shares. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not an Earnings Release (ER) as it focuses on financing, not operational results, and it is not a Share Issue/Capital Change (SHA) which typically covers splits or rights issues, although this involves new shares, the primary context is the fundraising event itself.
2023-01-30 English
NFL Biosciences lance une levée de fonds d’environ 2,5 millions d’euros
Capital/Financing Update Classification · 99% confidence The document is a press release dated January 30, 2023, announcing the launch of a fundraising effort ('levée de fonds') by NFL Biosciences, aiming to raise approximately 2.5 million euros through the issuance of new shares. It details the structure of the offering (reserved for professional investors and a public offer via PrimaryBid), the pricing range, and the intended use of proceeds (funding clinical trials). This content directly relates to the company raising capital and changing its capital structure. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document length is substantial (over 22k characters), confirming it is the primary announcement/report, not just a brief notification of publication (RPA/RNS).
2023-01-30 French
NFL Biosciences : Agenda de communication financière du 1er semestre 2023
Report Publication Announcement Classification · 99% confidence The document is titled "Agenda de communication financière du 1er semestre 2023" (Financial Communication Agenda for the first half of 2023). It explicitly lists future dates for key events, specifically the 'Résultats annuels 2022' (Annual Results) and the 'Assemblée générale annuelle' (Annual General Meeting). This document is not the actual report (like 10-K or ER) nor the AGM presentation itself, but rather an announcement detailing the schedule of upcoming corporate events and publications. This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports.
2023-01-17 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.